Search Results Search Sort by RelevanceMost Recent Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974. Policy Forum Feb 2019 What Are Important Ethical Implications of Using Facial Recognition Technology in Health Care? Nicole Martinez-Martin, JD, PhD Applications can identify and monitor patients. They can also diagnose genetic, medical, and behavioral conditions. AMA J Ethics. 2019;21(2):E180-187. doi: 10.1001/amajethics.2019.180. Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Policy Forum Mar 2016 Medical Malpractice Reform: Historical Approaches, Alternative Models, and Communication and Resolution Programs Joseph S. Kass, MD, JD and Rachel V. Rose, JD, MBA Alternatives to suing could help open communication between injured patients and clinicians. AMA J Ethics. 2016;18(3):299-310. doi: 10.1001/journalofethics.2016.18.3.pfor6-1603. Policy Forum Feb 2023 What the COVID-19 Pandemic Teaches Us About Pediatric Iatrogenic Risk Katherine Pumphrey, MD, MHA and Jessica Hart, MD, MHQS Pediatricians have been forced to navigate diagnostic uncertainty, hospital closures, limited staffing, and new infection control guidelines. AMA J Ethics. 2023;25(2):E130-132. doi: 10.1001/amajethics.2023.130. Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Policy Forum Nov 2022 Necessity for and Limitations of Price Transparency in American Health Care Harold A. Pollack, PhD, MPP More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline. AMA J Ethics. 2022;24(11):E1069-1074. doi: 10.1001/amajethics.2022.1069. Policy Forum Sep 2022 Roles of Environmental Services Workers’ Wages and Status in Patient Safety David Sine, DBioethics and Lloyd Duplechan This article offers a risk management standpoint on environmental services as a mission-critical function of any health care organization. AMA J Ethics. 2022;24(9):E876-882. doi: 10.1001/amajethics.2022.876. Policy Forum Feb 2005 What's Wrong with Quality of Life as a Clinical Tool? John S. Wyatt, MD, FRSPCH Virtual Mentor. 2005;7(2):183-186. doi: 10.1001/virtualmentor.2005.7.2.pfor1-0502. Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974.
Policy Forum Feb 2019 What Are Important Ethical Implications of Using Facial Recognition Technology in Health Care? Nicole Martinez-Martin, JD, PhD Applications can identify and monitor patients. They can also diagnose genetic, medical, and behavioral conditions. AMA J Ethics. 2019;21(2):E180-187. doi: 10.1001/amajethics.2019.180.
Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Policy Forum Mar 2016 Medical Malpractice Reform: Historical Approaches, Alternative Models, and Communication and Resolution Programs Joseph S. Kass, MD, JD and Rachel V. Rose, JD, MBA Alternatives to suing could help open communication between injured patients and clinicians. AMA J Ethics. 2016;18(3):299-310. doi: 10.1001/journalofethics.2016.18.3.pfor6-1603.
Policy Forum Feb 2023 What the COVID-19 Pandemic Teaches Us About Pediatric Iatrogenic Risk Katherine Pumphrey, MD, MHA and Jessica Hart, MD, MHQS Pediatricians have been forced to navigate diagnostic uncertainty, hospital closures, limited staffing, and new infection control guidelines. AMA J Ethics. 2023;25(2):E130-132. doi: 10.1001/amajethics.2023.130.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Policy Forum Nov 2022 Necessity for and Limitations of Price Transparency in American Health Care Harold A. Pollack, PhD, MPP More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline. AMA J Ethics. 2022;24(11):E1069-1074. doi: 10.1001/amajethics.2022.1069.
Policy Forum Sep 2022 Roles of Environmental Services Workers’ Wages and Status in Patient Safety David Sine, DBioethics and Lloyd Duplechan This article offers a risk management standpoint on environmental services as a mission-critical function of any health care organization. AMA J Ethics. 2022;24(9):E876-882. doi: 10.1001/amajethics.2022.876.
Policy Forum Feb 2005 What's Wrong with Quality of Life as a Clinical Tool? John S. Wyatt, MD, FRSPCH Virtual Mentor. 2005;7(2):183-186. doi: 10.1001/virtualmentor.2005.7.2.pfor1-0502.